Discovery of potent Plasmodium falciparum protein kinase 6 (PfPK6) inhibitors with a type II inhibitor pharmacophore
作者:Han Wee Ong、Anna Truong、Frank Kwarcinski、Chandi de Silva、Krisha Avalani、Tammy M. Havener、Michael Chirgwin、Kareem A. Galal、Caleb Willis、Andreas Krämer、Shubin Liu、Stefan Knapp、Emily R. Derbyshire、Reena Zutshi、David H. Drewry
DOI:10.1016/j.ejmech.2022.115043
日期:2023.3
group that contribute to antiplasmodial activity, cumulating in the discovery of compound 67, a PfPK6 inhibitor (IC50 = 13 nM) active against the P. falciparum blood stage (EC50 = 160 nM), and compound 79, a PfPK6 inhibitor (IC50 < 5 nM) with dual-stage antiplasmodial activity against P. falciparum blood stage (EC50 = 39 nM) and against P. berghei liver stage (EC50 = 220 nM).
疟疾是一种毁灭性的疾病,导致全球发病率和死亡率很高。对青蒿素联合疗法耐药性的上升表明有必要开发具有新作用机制的替代抗疟药。我们报告发现Ki8751作为必需激酶 PfPK6 的抑制剂。设计、合成并评估了 79 种衍生物的 PfPK6 抑制和抗疟原虫活性。通过群体效率分析,我们确定了与 II 型抑制剂药效团一致的支架上关键群体的重要性。我们强调了尾部基团上有助于抗疟原虫活性的修饰,最终发现了化合物67 (一种 PfPK6 抑制剂(IC 50 = 13 nM),对恶性疟原虫血液阶段(EC 50 = 160 nM)具有活性)和化合物79 ,一种 PfPK6 抑制剂 (IC 50 < 5 nM),对恶性疟原虫血液期 (EC 50 = 39 nM) 和伯氏疟原虫肝脏期 (EC 50 = 220 nM) 具有双阶段抗疟原虫活性。